



Building a New Open Innovation Ecosystem for Medical Research and Drug Discovery

Innovative Medicine Initiative (IMI) is one of the biggest public private partnership in the world, of which budget is €2B for 1st period (2008~2013) and €3.3B for 2nd period (2014-2020), and they celebrate 10 years anniversary in 2018.

At the seminar, Dr. Pierre Meulien, who is executive director of IMI, will talk about the drug discovery at IMI. In addition, Kyoto University speakers also present their drug discovery eco-system. The seminar provides deep knowledge of open innovation for drug discovery.

【Date】 Monday 2nd July 2018, 10:00~12:20 (reception 9:30~)

【Venue】 Seminar room, 3rd Floor of Med-Pharm Collaboration Bldg.

<http://www.ihk.med.kyoto-u.ac.jp/access>

【Capacity】 50 Registration is required **【Fee】** Free

【Language】 English

Hosted by Kyoto University Graduate School of Medicine.

10:00~10:10	Opening Remarks Shinji Uemoto (Dean, Kyoto U. Grad. Med.)
10:10~10:40	“One-stop drug discovery at Kyoto University” Masatoshi Hagiwara (Professor, Kyoto U. Grad. Med.)
10:40~10:50	“Translational research for practical applications” Eriko Sumi (Assistant Professor, iACT, Kyoto U. Hospital)
10:50~11:05	“One-Stop Clinical Bio-resource Project in Kyoto University Hospital” Manabu Muto (Professor, Kyoto U. Cancer Center)
11:05~11:10	Q&A
11:10~12:10	Keynote Lecture “The Innovative Medicines Initiative a European public private partnership accelerating open innovation” Dr. Pierre Meulien (Executive Director , Innovative Medicine Initiative)
12:10~12:20	Closing Remarks Masatoshi Hagiwara (Vice Dean, Kyoto U. Grad. Med.)

Contact: Kyoto University Medical Science and Business Liaison Organization

①Name, ②Organization/Position, ③Mail address are needed for registration. Deadline: 25th June
Mail: mi@kumbl.med.kyoto-u.ac.jp, Tel:075-366-7421 (ext. 19-7421)

Keynote Speaker



Dr. Pierre Meulien

Executive Director of Innovative Medicine Initiative

Pierre Meulien is executive director of the Innovative Medicines Initiative (IMI), a €5 billion public-private partnership between the European Union and the European pharmaceutical industry. At IMI, he is responsible for the overall management of the program, which works to improve and accelerate the drug development process by facilitating collaboration between the key players involved in health research. Previously, Meulien was president and CEO of Genome Canada, where he raised money and oversaw the launch of novel projects and networks in the field of genomics-based technologies. Prior to that, he was chief scientific officer for Genome British Columbia and was the founding CEO of the Dublin Molecular Medicine Center. Meulien also worked with the French biotechnology company Transgene and with Aventis Pasteur (now Sanofi Pasteur). He has a Ph.D. in molecular biology from the University of Edinburgh and carried out a postdoctoral fellowship at the Institut Pasteur in Paris.